Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, 92037, USA.
Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
Cancer Lett. 2019 May 1;449:145-162. doi: 10.1016/j.canlet.2019.02.012. Epub 2019 Feb 14.
Inhibition of ubiquitin ligases with small molecule remains a very challenging task, given the lack of catalytic activity of the target and the requirement of disruption of its interactions with other proteins. Siah1/2, which are E3 ubiquitin ligases, are implicated in melanoma and prostate cancer and represent high-value drug targets. We utilized three independent screening approaches in our efforts to identify small-molecule Siah1/2 inhibitors: Affinity Selection-Mass Spectrometry, a protein thermal shift-based assay and an in silico based screen. Inhibitors were assessed for their effect on viability of melanoma and prostate cancer cultures, colony formation, prolyl-hydroxylase-HIF1α signaling, expression of selected Siah2-related transcripts, and Siah2 ubiquitin ligase activity. Several analogs were further characterized, demonstrating improved efficacy. Combination of the top hits identified in the different assays demonstrated an additive effect, pointing to complementing mechanisms that underlie each of these Siah1/2 inhibitors.
小分子抑制泛素连接酶仍然是一项极具挑战性的任务,因为目标缺乏催化活性,并且需要破坏其与其他蛋白质的相互作用。Siah1/2 是 E3 泛素连接酶,与黑色素瘤和前列腺癌有关,是高价值的药物靶点。我们利用三种独立的筛选方法来鉴定小分子 Siah1/2 抑制剂:亲和选择-质谱法、基于蛋白质热移位的测定法和基于计算的筛选。评估了抑制剂对黑色素瘤和前列腺癌细胞培养物活力、集落形成、脯氨酰-羟化酶-HIF1α 信号、选定的 Siah2 相关转录物表达和 Siah2 泛素连接酶活性的影响。进一步对几种类似物进行了表征,证明了其疗效的提高。在不同测定中鉴定出的最佳组合显示出相加效应,表明这些 Siah1/2 抑制剂的作用机制是互补的。